PharmPK Discussion - UGT 2B7 Metabolism

• On 23 Mar 2007 at 07:34:01, "Nagaraju Poola" (poolan.-at-.wyeth.com) sent the message
  

  
  Dear Group Members,
  Are there drugs that are primarily metabolized by UGT 2B7 besides
  carbamazepine and valproate?
  Thank you in advance.
  Raju
  
  

  Back to the Top

• On 23 Mar 2007 at 10:23:21, sripal reddy mada (srmada.-at-.yahoo.com) sent the message
  

  
  The following message was posted to: PharmPK
  
  Hi Raju, Morphine Metabolize primarily by UGT2B7 to Morphine
  Glucuronide.
  So people use it as a specific proble for UGT2B7 inducer/inhibitor
  screening.
  Sripal
  
  

  Back to the Top

• On 23 Mar 2007 at 13:35:49, "Rioux, Nathalie" (nrioux.-at-.neurochem.com) sent the message
  

  
  The following message was posted to: PharmPK
  
  Raju,
  
  AZT (zidovudine)is glucuronidate via 2B7 (some papers were published
  suggesting that it could be used as probe substrate).
  
  Nathalie
  
  

  Back to the Top

• On 23 Mar 2007 at 17:18:41, "Fatemeh Akhlaghi, PhD" (fak4939u.-a-.postoffice.uri.edu) sent the message
  

  
  The following message was posted to: PharmPK
  
  Hello
  
  The immunosuppressive agent mycophenolic acid (MPA) is metabolized by
  UGT2B7
  to an acyl glucuronide (acyl-MPAG) metabolite .  It is a minor but
  important
  pathway because the acyl-MPAG is believed to be toxic.
  
  Fatemeh
  
  Fatemeh Akhlaghi, PharmD, PhD
  Associate Professor in Pharmacokinetics
  Biomedical and Pharmaceutical Sciences (BPS)
  University of Rhode Island
  125 Fogarty Hall, 41 Lower College Road
  Kingston, RI 02881, USA
  
  Phone/Fax: (401) 874 9205/(401) 874 2181
  Email: fatemeh.-at-.uri.edu
  Laboratory Website: http://www.uri.edu/pharmacy/faculty/aps/akhlaghi/
  index
  
  

  Back to the Top

• On 26 Mar 2007 at 08:46:51, "Henri Merdjan" (henri.-a-.novexel.com) sent the message
  

  
  The following message was posted to: PharmPK
  
  Dear Raju,
  
  I'm thinking of clofibric acid, diclofenac and zidovudine (Williams
  JA, Hyland R, Jones BC, et al. Drug-drug interactions for UDP-
  glucuronyl transferases substrates: a pharmacokinetic explanation for
  typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos
  (2004) 32:1201-1208.)
  
  Hope this helps,
  
  Henri MERDJAN
  Head of Drug Metabolism and Pharmacokinetics
  NOVEXEL S.A., Parc Biocitech, 102 Route de Noisy
  F-93230 Romainville, France
  
  

  Back to the Top

Copyright 1995-2011 David W. A. Bourne (david@boomer.org)